



## **Adherium Accelerates Commercialisation with Largest US Allergy & Asthma Practice**

- **Hailie® platform available to 300,000 plus Allergy Partners patients**
- **Hailie provides real-time data for patient feedback for self-management and improved health outcomes**
- **Hailie enables doctors to bill for remote patient management, generating repeat, multi-year revenues**
- **Initial roll out to three states with new employee training starting this month and expansion to more states to follow this calendar year**

**Melbourne, Australia – 04 August 2023:** Leading digital health company Adherium Limited (ASX: ADR) has signed a collaboration agreement with US-based Allergy Partners to transform asthma management for its more than 300,000 patients across 130 sites in 20 states.

Allergy Partners is the largest allergy and asthma practice in the US. It will integrate Adherium's leading-edge Hailie platform consisting of a growing portfolio of sensor technology, user app, clinician portal, and cloud-based data solution into its care approach. The end-to-end Hailie platform will enable Allergy Partners patients to better manage their asthma, and its clinicians to tailor care with data supporting medication adherence, behavioural influencing, escalations, and interventions while enable billing for remote patient management.

*"Adherium welcomes this ground breaking partnership with Allergy Partners – part of our push to accelerate commercialisation in the US through strategic, large-scale partnerships across health care systems. Adherium and Allergy Partners are combining their expertise to make a powerful impact to improve patient lives with benefits for all stakeholders",* said Rick Legleiter, Adherium CEO.

Allergy Partners' Chief Medical Officer, William McCann, MD, called the Hailie platform, *"a game-changer enabling patients to actively manage their conditions, aligning*

*perfectly with Allergy Partners' mission to improve allergy and asthma patients' lives."*

Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. Hailie's clinically proven, unique sensors capture when and how an inhaler is being used, radically improving adherence and patient self-management. This enables timely interventions and tailored treatments to improve health outcomes and greatly reduce hospital admissions.

Following four US FDA 510(k) market clearances of the next generation Hailie sensors, Adherium progressed on its regulatory strategy to 79% coverage for sensors capturing physiological data such as inhalation flow rate, and 91% coverage for adherence tracking of US top 20 branded inhaler medications by sales volume. Hailie is the only FDA 510(k) cleared drug agnostic digital sensor available today to offer physiological data insights on inhaler technique.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.

Adherium and Allergy Partners have agreed an implementation plan with an initial roll out to three US states this quarter with continued expansion to more locations across its markets later this calendar year. Demonstrating its commitment to the collaboration, Allergy Partners hired a new employee that started this week as the internal program manager at the corporate headquarters to champion the implementation. Likewise, Adherium is investing by expanding its US-based customer service and application support team with new staff onboarded this month. To support the scale-up there is sufficient sensor stock in the US to satisfy demand and Adherium's contract manufacturer has the ability to ramp-up production as required.

For more information about Adherium and Hailie, visit [www.adherium.com](http://www.adherium.com).

This ASX announcement was approved and authorised for release by the Adherium Board of Directors.

**Enquiries:**

Rick Legleiter

CEO

Adherium Limited

[investors@adherium.com](mailto:investors@adherium.com)

Rudi Michelson

Monsoon Communications

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**-ENDS-**

**About Adherium**

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US, UK and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>

**About the Hailie Platform**

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease.

Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study.

The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.

### **About Allergy Partners**

Allergy Partners is the largest allergy and asthma practice in the United States, consisting of a network of 150 allergists and immunologists over 130 locations across 20 US states. Headquartered in Asheville, North Carolina, Allergy Partners provides comprehensive care for patients with allergies and asthma across the nation. They are committed to delivering exceptional medical expertise, patient-centered care, and innovative solutions to improve the lives of individuals with respiratory conditions.